ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.735,75
-1,32%
S&P 500
5.867,08
0,00%
Dow Jones
42.342,24
0,00%
Euro vs US Dollar
1,04076
0,42%
Bitcoin
95.469,61
-2,04%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) News

BCRX

BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BCRX
DatumZeitQuelleÜberschriftSymbolFirma
17/12/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/12/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/12/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/12/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/12/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
16/12/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/12/202422h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/12/202422h15GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/12/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
18/11/202408h00GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in IrelandNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/11/202413h00GlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/11/202423h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/11/202413h00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/11/202413h00GlobeNewswire Inc.BioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
24/10/202414h00GlobeNewswire Inc.BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
21/10/202413h00GlobeNewswire Inc.BioCryst to Report Third Quarter 2024 Financial Results on November 4NASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/10/202413h00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/10/202413h00GlobeNewswire Inc.BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/10/202413h00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/10/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
02/10/202413h00GlobeNewswire Inc.BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeNASDAQ:BCRXBioCryst Pharmaceuticals Inc
30/09/202413h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
30/09/202413h00GlobeNewswire Inc.U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National StockpileNASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/09/202413h00GlobeNewswire Inc.BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/09/202418h09Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/09/202408h00GlobeNewswire Inc.BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/09/202413h00GlobeNewswire Inc.BioCryst Appoints Dr. Donald Fong Chief Medical OfficerNASDAQ:BCRXBioCryst Pharmaceuticals Inc
04/09/202413h00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/09/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:BCRX

Kürzlich von Ihnen besucht

NYSE
DIS
Walt Disney
TG
NOV
Novo Nordisk
DBI
DAX
DAX
COIN
AVAXUSD
Avalanche
TG
ALV
Allianz
DBI
SDXP
SDAX
NASDAQ
NVDA
NVIDIA
TG
TUI1
Tui
COIN
DOGEUSD
Dogecoin
CCOM
US100
US Tech 100
NASDAQ
AAPL
Apple
USOTC
RHHBY
Roche (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
SPY
SPDR S&P 500
TG
MBG
MercedesBenz
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten